Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001596771-16-000158
Filing Date
2016-10-06
Accepted
2016-10-06 16:13:44
Documents
2
Period of Report
2016-10-05

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 3  
1 PRIMARY DOCUMENT primary_doc.xml 3 1577
2 POWER OF ATTORNEY poagoldengemphire.txt EX-24 2983
  Complete submission text file 0001596771-16-000158.txt   5958
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Issuer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address
Golden Lee Scott (Reporting) CIK: 0001686217 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37809 | Film No.: 161924990